SCHEMBL436411

SCHEMBL436411

COc1cccc(CC(=O)Nc2nc(-c3ccnc(F)c3)cs2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 10/20 1.00
ROCK1 Q13464 10/20 1.00
MEN1 O00255 2/20 0.81
KMT2A Q03164 2/20 0.81
PRKACA P17612 4/20 0.79
HTT P42858 1/20 0.73
ROCK2 O75116 1/20 0.70
MAPT P10636 1/20 0.66
ALDH1A1 P00352 1/20 0.65
RAB9A P51151 1/20 0.65
ELOVL1 Q9BW60 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL438700 0.89 CYP3A4 (1.00) CYP3A4ROCK1MEN1KMT2APRKACA
SCHEMBL439520 0.89 CYP3A4 (1.00) CYP3A4ROCK1MEN1KMT2APRKACA
SCHEMBL436413 0.89 CYP3A4 (1.00) CYP3A4ROCK1MEN1KMT2APRKACA
SCHEMBL439202 0.89 CYP3A4 (1.00) CYP3A4ROCK1MEN1KMT2APRKACA
SCHEMBL439512 0.88 ROCK1 (1.00) CYP3A4ROCK1MEN1KMT2APRKACA
SCHEMBL439408 0.87 ROCK1 (0.77) CYP3A4ROCK1MEN1KMT2APRKACA
SCHEMBL3252649 0.87 ROCK1 (1.00) CYP3A4ROCK1MEN1KMT2APRKACA
SCHEMBL438705 0.87 CYP3A4 (0.88) CYP3A4ROCK1MEN1KMT2APRKACA
SCHEMBL437321 0.87 CYP3A4 (1.00) CYP3A4ROCK1MEN1KMT2APRKACA
SCHEMBL439210 0.86 ROCK1 (0.83) CYP3A4ROCK1MEN1KMT2APRKACA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8278306-B2 C-met protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-10-02 US disclosed
US-8278306-B2 C-met protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-10-02 US disclosed
US-20120065213-A1 C-MET PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-15 US disclosed
US-20120065213-A1 C-MET PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-15 US disclosed
US-8058271-B2 Selective inhibitors of rock protein kinase and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-11-15 US disclosed
US-8058271-B2 Selective inhibitors of rock protein kinase and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-11-15 US disclosed
EP-2032562-B1 SELECTIVE INHIBITORS OF ROCK PROTEIN KINASE AND USES THEREOF VERTEX PHARMA (US) 2010-08-25 EP disclosed
WO-2007133622-A2 SELECTIVE INHIBITORS OF ROCK PROTEIN KINASE AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-11-22 WO disclosed
US-20070270386-A1 Selective inhibitors of rock protein kinase and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2007-11-22 US disclosed
US-20070270386-A1 Selective inhibitors of rock protein kinase and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2007-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070270386-A1 Selective inhibitors of rock protein kinase and uses thereof ROCK1, ROCK2, MYLK CYP3A4 4395/4885ROCK1 1/4885MEN1 1248/4885
US-20120065213-A1 C-MET PROTEIN KINASE INHIBITORS MET, PRKCH, MYLK CYP3A4 3859/4885ROCK1 4/4885MEN1 275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.